Prevention of Neurite Spine Loss Induced by Dopamine D2 Receptor Overactivation in Striatal Neurons

Peng Zheng1, Qian Peter Su2, Dayong Jin2

  • 1Illawarra Health and Medical Research Institute (IHMRI) and School of Medicine, University of Wollongong, Wollongong, NSW, Australia.

Insights

Excessive dopamine D2 receptor (D2R) and DISC1 complex formation impairs neuronal connections in psychosis. Disrupting this complex with TAT-D2pep protected neuronal morphology and dendritic spines, offering a potential treatment strategy.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Psychiatry

Background:

  • Psychosis is linked to impaired neuronal connectivity.
  • Excessive dopamine D2 receptor (D2R) - disrupted in schizophrenia 1 (DISC1) complexes offer new insights into psychotic symptoms.

Purpose of the Study:

  • To investigate how excessive D2R-DISC1 complex formation affects neurite growth and dendritic spines in striatal neurons.
  • To explore the therapeutic potential of disrupting D2R-DISC1 complexes.

Main Methods:

  • Utilized fluorescence resonance energy transfer (FRET), stochastic optical reconstruction microscopy (STORM), and cell-penetrating peptide delivery.
  • Studied cultured striatal neurons from mouse pups.

Main Results:

  • D2R and DISC1 interact within striatal neurons, accumulating in dendritic spines.
  • Disruption of D2R-DISC1 complexes using TAT-D2pep protected neuronal morphology and dendritic spines.
  • TAT-D2pep prevented neurite and dendritic spine loss, restoring synaptophysin and PSD-95 levels.

Conclusions:

  • Excessive D2R-DISC1 complex formation contributes to neurite and dendritic spine deficits in psychosis.
  • Disrupting D2R-DISC1 complexes with TAT-D2pep shows therapeutic potential for schizophrenia-associated deficits.
  • Neuropeptide Y (NPY) and GSK3β are involved in the protective effects of TAT-D2pep.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
830
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K